Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
0qZQbG6c08APT0th
